 In the study, the investigators will compared four arms of combined therapy: clopidogrel with rosuvastatin; or clopidogrel with simvastatin; or ticagrelor with rosuvastatin; or ticagrelor with simvastatin. The investigators hypothesis is that the improvement of microcirculation with rosuvastatin and ticagrelor synergic pleiotropic effects may decrease the infarcted mass area, resulting in better left ventricular ejection fraction when compared to the other combined therapies. 